Trending Stocks: Repros Therapeutics Inc. (NASDAQ:RPRX), The Wet Seal, Inc. (NASDAQ:WTSL), Galena Biopharma Inc. (NASDAQ:GALE)
Dallas, Texas, 09/29/2014 (ustrademedia) – Repros Therapeutics Inc. (NASDAQ:RPRX) recently reported top-line results from the one of the two identical pivotal studies comparing ZA-304, Androxal® to placebo and Androgel® 1.62, a leading FDA-approved topical gel. Repros noted that ZA-304 met the primary efficacy endpoints, demonstrating the reproducibility of the prior study findings. In addition, the study also found ZA-304 to be superior in both co-primary endpoints as compared to a topical gel. The study was designed to enroll total 120 males, 40 each into three study arms. Primary study endpoints were the percentage of subjects considered to be responders and percentage change in average sperm concentration from baseline.
The Wet Seal, Inc. (NASDAQ:WTSL) recently announced the appointment of Jon Kubo as its Executive Vice President and Chief Digital Officer, effective October 6, 2014. In this newly created role, Mr. Kubo will be responsible for digital marketing, e-commerce and the IT organization to seamlessly integrate digital consumer experiences across the business touch points. Previously, Mr. Kubo served as Chief Information Officer and Head of e-commerce at The Wet Seal from 2005 through 2011. His emphasize on innovative mobile and social consumer engagement programs helped the company to achieve highest sales volume in the e-commerce business during his tenure.
Galena Biopharma Inc. (NASDAQ:GALE) released a report pertaining to its 2012-2014 market visibility campaigns and the insiders’ sale of shares in the 1Q14. The former Special Committee of the Company’s Board of Directors prepared this report. Galena’s Board recently formed a Special Litigation Committee as a result of new claims and allegations in the derivative litigation. The new Committee has the full authority to access, use and disclose the work of the former Special Committee. Galena President and CEO, Mark W. Schwartz expressed that the company will not comment on the report in order to maintain the independence and integrity of the Special Litigation Committee’s investigation.